Core Viewpoint - Zhendermedical's stock closed at 24.6 yuan, up 1.74%, with a rolling PE ratio of 18.06, marking a 215-day low, and a total market value of 6.555 billion yuan [1] Group 1: Company Performance - For Q1 2025, the company reported revenue of 999.2 million yuan, a year-on-year increase of 2.87%, and a net profit of 51.2419 million yuan, a year-on-year decrease of 30.19%, with a gross profit margin of 34.28% [1] - As of March 31, 2025, the number of shareholders increased to 24,690, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2: Industry Comparison - The average PE ratio for the medical device industry is 59.32, with a median of 39.97, placing Zhendermedical at 38th in the industry ranking [1][2] - Other companies in the industry have varying PE ratios, with the highest being 20.96 for Antu Biology and the lowest at 11.61 for Jiuan Medical [2]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Zhendermedical, which closed at 23.68 yuan with a PE ratio of 17.38, marking a new low in 165 days, and a total market capitalization of 6.31 billion yuan [1][2] - The average PE ratio for the medical device industry is 56.58, with a median of 39.97, positioning Zhendermedical at 37th place within the industry [1][2] - As of March 31, 2025, Zhendermedical has 24,690 shareholders, an increase of 1,808 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - Zhendermedical specializes in the research, production, and sales of medical and health products, with key offerings in basic care, surgical infection control, pressure treatment, stoma care, and modern wound care [1] - The latest quarterly report for Q1 2025 shows Zhendermedical achieved a revenue of 999.2 million yuan, a year-on-year increase of 2.87%, while net profit was 51.24 million yuan, reflecting a year-on-year decrease of 30.19%, with a gross margin of 34.28% [1]

Core Viewpoint - Zhendermedical's stock closed at 23.22 yuan, down 1.32%, with a rolling PE ratio of 17.04 times and a total market value of 6.187 billion yuan [1] Company Summary - Zhendermedical specializes in the research, production, and sales of medical and health products, focusing on basic care, surgical infection control, pressure treatment and fixation, ostomy and modern wound care, and infection control protection [1] - The company has received multiple technical awards, including provincial-level key enterprise research institutes and high-tech enterprise certifications [1] - For Q1 2025, Zhendermedical reported revenue of 999.2 million yuan, a year-on-year increase of 2.87%, and a net profit of 51.2419 million yuan, a year-on-year decrease of 30.19%, with a gross profit margin of 34.28% [1] Industry Summary - The average PE ratio for the medical device industry is 55.76 times, with a median of 39.14 times, placing Zhendermedical at the 36th position in the industry [1] - The industry includes various companies with differing PE ratios, such as Ji'an Medical at 11.18 times and Yuyue Medical at 20.19 times, indicating a wide range of valuations within the sector [2]

最新一期业绩显示，2025年一季报，公司实现营业收入9.92亿元，同比2.87%；净利润5124.19万元，同 比-30.19%，销售毛利率34.28%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)5振德医疗17.3716.371.1063.04亿行业平均 57.5153.344.97120.28亿行业中值41.2539.962.9558.75亿1九安医疗11.2611.380.89189.95亿2英科医疗 15.0516.231.34237.81亿3山东药玻16.1716.221.86152.96亿4新华医疗16.9415.701.38108.60亿6奥美医疗 17.5417.191.8063.39亿7九强生物17.9216.672.2088.77亿8康德莱18.7518.761.5540.40亿9维力医疗 18.7920.082.3644.05亿10奥泰生物19.3120.361.5661.58亿11鱼跃医疗20.2319.842.73358.29亿12安图生物 21.1920.232.72241.60亿 8月12日，振德医疗今日收盘23.66元，上涨3.59%，滚动市盈率PE（当前股价与前四 ...

Core Viewpoint - Zhendermedical's stock closed at 22.84 yuan, up 2.79%, with a rolling PE ratio of 16.76, marking a new low in 158 days, and a total market value of 6.086 billion yuan [1] Company Summary - Zhendermedical specializes in the research, production, and sales of medical and health products, focusing on basic care, surgical infection control, pressure treatment and fixation, ostomy and modern wound care, and infection control protection [1] - The company has received multiple technical awards, including provincial-level key enterprise research institutes and high-tech enterprise certifications, and has passed the national high-tech enterprise review [1] - For Q1 2025, Zhendermedical reported revenue of 999.2 million yuan, a year-on-year increase of 2.87%, and a net profit of 51.2419 million yuan, a year-on-year decrease of 30.19%, with a gross profit margin of 34.28% [1] Industry Summary - The average PE ratio for the medical device industry is 56.56, with a median of 39.76, placing Zhendermedical at 35th in the industry ranking [1] - As of Q1 2025, three institutions held shares in Zhendermedical, with a total of 1.4513 million shares valued at 3.1 million yuan [1] - The industry average market value is 11.897 billion yuan, with Zhendermedical's market value significantly lower at 6.086 billion yuan [2]

Core Insights - Zhendermedical's stock closed at 22.42 yuan, up 1.04%, with a rolling PE ratio of 16.46, marking a new low in 145 days, and a total market capitalization of 5.974 billion yuan [1] - The average PE ratio for the medical device industry is 54.32, with a median of 38.11, placing Zhendermedical at 36th position in the industry ranking [1] - As of the first quarter of 2025, three institutions held shares in Zhendermedical, with a total of 1.4513 million shares valued at 0.031 billion yuan [1] Company Overview - Zhendermedical specializes in the research, production, and sales of medical and health products, focusing on basic care, surgical infection control, pressure treatment and fixation, ostomy and modern wound care, and infection control protection [1] - The company has received multiple technical awards, including recognition as a provincial key enterprise research institute and a national high-tech enterprise [1] Financial Performance - In the first quarter of 2025, Zhendermedical reported revenue of 0.992 billion yuan, a year-on-year increase of 2.87%, while net profit was 51.2419 million yuan, reflecting a year-on-year decrease of 30.19%, with a sales gross margin of 34.28% [1]

Core Viewpoint - Zhendermedical's stock closed at 21.87 yuan, up 2.53%, with a rolling PE ratio of 16.05, marking a new low in 75 days, and a total market value of 5.827 billion yuan [1] Company Summary - Zhendermedical specializes in the research, production, and sales of medical and health products, focusing on basic care, surgical infection control, pressure treatment and fixation, stoma and modern wound care, and infection control protection [1] - The company has received multiple technical awards, including provincial key enterprise research institutes and high-tech enterprise certifications, and has passed the national high-tech enterprise review [1] - For Q1 2025, Zhendermedical reported revenue of 999.2 million yuan, a year-on-year increase of 2.87%, and a net profit of 51.2419 million yuan, a year-on-year decrease of 30.19%, with a gross profit margin of 34.28% [1] Industry Summary - The average PE ratio for the medical device industry is 53.52, with a median of 37.14, placing Zhendermedical at 36th in the industry ranking [2] - The industry average and median PE ratios indicate a higher valuation compared to Zhendermedical's current PE ratio of 16.05 [2] - The total market value of Zhendermedical is 5.827 billion yuan, which is significantly lower than the industry average market value of 111.58 billion yuan [2]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Zhendermedical, indicating a decline in net profit despite a slight increase in revenue [1][2] - Zhendermedical's closing stock price is 20.86 yuan, with a rolling PE ratio of 15.31 times, which is significantly lower than the industry average of 49.70 times [1][2] - The company has a total market capitalization of 5.558 billion yuan, ranking 36th in the medical device industry based on PE ratio [1][2] Group 2 - As of the first quarter of 2025, 15 institutions hold shares in Zhendermedical, with a total holding of 154.3014 million shares valued at 3.331 billion yuan [1] - The main business of Zhendermedical includes the research, production, and sales of medical and health products, with key products in basic care, surgical infection control, pressure treatment, and modern wound care [1] - The latest financial report shows that for the first quarter of 2025, the company achieved an operating income of 999.2 million yuan, a year-on-year increase of 2.87%, while net profit was 51.2419 million yuan, a year-on-year decrease of 30.19% [1]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Zhend Medical, which closed at 20.55 yuan with a PE ratio of 15.08, marking a 15-day low, and a total market capitalization of 5.476 billion yuan [1][2] - Zhend Medical ranks 34th in the medical device industry, which has an average PE ratio of 49.51 and a median of 36.17 [1][2] - As of the first quarter of 2025, 15 institutions hold shares in Zhend Medical, with a total holding of 154.3014 million shares valued at 3.331 billion yuan [1] Group 2 - The main business of Zhend Medical includes the research, production, and sales of medical and health products, focusing on basic care, surgical infection control, pressure treatment, stoma care, and modern wound care [1] - The latest financial results for the first quarter of 2025 show Zhend Medical achieved a revenue of 999.2 million yuan, a year-on-year increase of 2.87%, while net profit was 51.2419 million yuan, reflecting a year-on-year decrease of 30.19%, with a gross profit margin of 34.28% [1]